Genentech mutant pi3ka degrader inovalisib gdc-0077 structure

isoform-selective mutant PI3Kα degrader

oral <9 mg QD, Ph. III in HR+/HER2- BC

from cellular characterization of PI3Ki and opt.

inovalisib (GDC-0077)

Genentech, South San Francisco, CA

The Genentech PI3Kα isoform-selective kinase inhibitor and mutant PI3Kα degrader inavolisib selectively depletes the oncogenic mutant p110α catalytic subunit of PI3Kα in cancer cells with active receptor tyrosine kinase…

     this content is exclusive to
    Premium members

    Upgrade to a Premium Drug Hunter membership to unlock the full content and start reading now.